Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NOTICE OF ANNUAL GENERAL MEETING IN NAXS AB (publ)

Not for release, publication or distribution, directly or indirectly, in or into the United States, Hong Kong, Canada, Japan or Australia, or any other jurisdiction in which the distribution or release would be unlawful. N.B. The English text is an in-house translation. In the event of any discrepancies between the text in this document and the Swedish document, the latter shall prevail. The shareholders of NAXS AB (publ), reg. no. 556712-2972, with its registered office in Stockholm (the “Company” or “NAXS”), are hereby invited to the annual general meeting (the “Meeting”) on

Scandic Nürnberg Central to open its doors

Tomorrow marks the opening of Scandic’s first hotel in Nürnberg, the second largest metropolitan area in Bavaria. The new hotel is an important step in the company’s expansion in Germany. With 311 rooms and event facilities for up to 800 people, the newly renovated hotel has been rebranded as a Scandic hotel since it was taken over from Pandox. Scandic Nürnberg Central will be operated by Scandic pursuant to a long-term revenue-based lease agreement from March 1, 2024.Scandic Nürnberg Central is located in the heart of the city, just a few minutes’ walk from the historic district and

Sensys Gatso’s partner signs contract for traffic safety solution in Finland, worth estimated SEK 20 million

Sensys Gatso Group, a global leader in traffic safety solutions, has through its partner Destia Oy, signed a contract with the procuring organisations Fintraffic and The National Police board of Finland for the delivery of traffic-safety cameras in Finland. Sensys Gatso’s part for the delivery of traffic-safety cameras under the procurement award, is estimated to be worth SEK 20 million, over the 4 year contract period.The award of the procurement was announced January 12. Sensys Gatso’s partner Destia OY has now signed the contract with the procuring organisations Fintraffic and The

Gaming Innovation Group – Exercise of options and mandatory notification of trade

Justin Psaila, CFO and primary insider of Gaming Innovation Group Inc. (GiG), has today exercised his options to buy 45,000 shares in GiG, whereof 30,000 at a share price of NOK 15.00 and 15,000 at a share price of NOK 22.00. After this transaction, Justin Psaila will own 47,100 shares and 15,000 options in GiG. Claudio Caruana, General Counsel and primary insider of Gaming Innovation Group Inc. (GiG), has today exercised his options to buy 30,000 shares in GiG at a price of NOK 15.00 per share. After this transaction, Claudio Caruana will own 30,100 shares and 30,000 options in GiG.

Nordea cancels repurchased shares

Nordea Bank AbpStock exchange release – Total number of voting rights and capital29 February 2024 at 9.15 EET Nordea has today cancelled 15,912,565 treasury shares in line with the decision by the Board of Directors. The shares were held for capital optimisation purposes and acquired through share buy-backs. The cancellation brings the total number of shares in Nordea to 3,505,587,395. The total number of votes attached to the shares is 3,505,587,395. The cancellation of the shares was registered with the Finnish Trade Register on 29 February 2024. The company holds 4,787,

Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and its partner Eisai will present new data on lecanemab (brand name: Leqembi®) at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), to be held in Lisbon, Portugal and virtually, March 5-9. In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic’s founder Professor Lars Lannfelt.Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and

From anonymity to recognition: The challenge of underdiagnosis and misdiagnosis in rare diseases

As we highlight Rare Disease Day, it’s crucial to focus on the often-overlooked issue of underdiagnosis and misdiagnosis in conditions like Arginase 1 Deficiency (ARG1-D), a progressive genetic metabolic disorder characterized by elevated plasma arginine levels, leading to serious health issues. ARG1-D presents with progressive neurological impairment, developmental delay, progressive spasticity and intellectual disability. The invisibility of rare diseases like ARG1-D in both public awareness and medical practice results in delayed interventions or even the omission of relevant treatments,

Fazer Group’s Annual Review 2023 published

Fazer’s Annual Review, Financial Review and Corporate Governance Report have been published today. These reports provide a comprehensive overview of the company's business and sustainability performance, and governance practices in 2023.Despite encountering a challenging market in 2023, Fazer's operational performance was good, and the demand for the products remained high throughout the year. Fazer’s Annual Review gives an in-depth look into Fazer’s year in 2023 and the path forward as a Food Experience Company. The Annual Review is available in Finnish, Swedish, and English and

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In February, at the request of shareholders, 6,410 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,251,072,876. The total number of registered shares in the company amounts to 702,342,489 of which 60,970,043 are Class

Q4 2023 Interim financial report

FINANCIAL HIGHLIGHTS· Group revenue of SEK 222.4m (SEK 235.0m). · Gross profit margin 44.7% (40.7%). · EBITDA of SEK 27.0m (SEK 23.2m). · Net operating cash flow SEK 28.6m (SEK 27.5m). · Sale of vacuum business, Sibilia Nordic. · New cooperation with supplier of smart lockers. · The Company has engaged Arctic Securities and Pareto Securities to explore refinancing options for the outstanding SEK 285m senior secured bond issue maturing 5 May 2024 (ISIN SE0015938493). · Order intake was SEK 188.5m (SEK 241.9m), and order backlog of SEK 130.3m (SEK 146.6m).

Optomed Annual Report 2023 published

Optomed Plc Stock Exchange Release 29  February 2024 at 9.00, Helsinki Optomed Annual Report 2023 published Optomed's Annual Report 2023 has been published. The Annual Report includes the company's consolidated and parent company financial statements, the report of the board of directors, the auditor’s report, corporate governance statement and remuneration report for governing bodies.   Optomed's Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements. KPMG Oy Ab, authorised public accountants, has provided an

Q4 and full year report January – December 2023

Change in executive leadership and solid cash positionHighlights fourth quarter 2023 · Cash at the end of December 2023 was EUR 20.7m (52.3 at December 2022) · Gross ERC at the end of December 2023 was EUR 280m (283 at December 2022) · Gross collections amounted to EUR 16.4m (16.4)* · Net collections amounted to EUR 14.3m (14.2)* · Cash EBITDA amounted to EUR 9.5m (10.2)* · Acquired E-Kancelaria, a Polish loan servicing and debt collection company, through its 75% owned subsidiary AxFina Highlights full year 2023 · Gross collections amounted to EUR 55.9m (70.8)*

Change in number of shares and votes in Viaplay Group

Viaplay Group AB (publ) (“Viaplay Group”) today announces that as of 29 February 2024, the total number of shares in Viaplay Group amounts to 4,579,122,244, and the total number of votes in Viaplay Group amounts to 4,583,906,068. As part of the recapitalisation programme announced by Viaplay Group on 1 December 2023, the extraordinary general meeting on 10 January 2024 resolved to reduce the nominal value per share to SEK 0.06 per share, and to approve a directed issue of 3,129,655,316 new class B shares, a rights issue of 870,344,684 new class B shares and a directed issue of 500,000,

Nurminen Logistics Plc’s Financial Statement Release for 1 Jan.— 31 Dec. 2023: The group achieved the best comparable operating result in its history, EUR 21.5 million

Nurminen Logistics Plc                            Financial Statement Release   February 29, 2024, 9.00 a.m.  This release is a summary of Nurminen Logistics' Financial Statement Release January-December 2023. The full report is attached to this stock exchange release and is available on Nurminen Logistics’ website at nurminenlogistics.com/investors/publications/ The year 2023 was a record-breaking year for the group. The net sales for 2023 amounted to EUR 128.0 million and comparable operating result to EUR 21.5 million. The group's relative profitability, measured by operating

OssDsign appoints Tom Buckland as Chief Technical Officer

OssDsign AB (publ.) today announces that the company’s current VP of Strategy, Business Development and Regulatory Affairs, Tom Buckland, has been appointed Chief Technical Officer (CTO). The promotion is a key part of the company’s change of direction into a pure-play orthobiologics company focusing exclusively on the U.S. Market.Tom Buckland, currently VP of Strategy, Business Development and Regulatory Affairs, will in his new role be responsible for Operations & Manufacturing, Research & Development as well as Quality Assurance and Regulatory Affairs.   “Since the Acquisition of

Interim report 4, October – December 2023

Fourth quarter October 1 – December 31, 2023 Group · Operating income amounted to SEK 8,428K (SEK 8,121K) · Operating profit amounted to SEK 814K (SEK -6,559K) · Net profit after income taxes amounted to SEK 831K (SEK -6,875K) · Net profit per share after income taxes amounted to SEK 0.03 (SEK -0.44) (Amounts within parentheses refer to the corresponding figures for the same period the prior year) Full year January 1 – December 31, 2023 Group · Operating revenue amounted to SEK 26,999K (21,664K). · Operating profit amounted to SEK -15,375K (-28,230K). ·

Cambio Year End Report Q4 2023

We had a strong fourth quarter, characterized by solid profitable growth and important customer wins. Customer Group KGC (Kundgrupp Cosmic), which consists of eight Swedish regions and one private care giver, has signed an extension of its COSMIC contract for another 5 years with 3 additional option years. This is a testament to the strong relationship between KGC and Cambio that has been developed over the last years. In the fourth quarter, we received a major order worth 84 MSEK to provide additional functionality to KGC, which will be delivered during 2023 and 2024. The order

Year-end report January – December 2023

Oslo, Norway, February 29, 2024 - Genetic Analysis AS (the "Company", Ticker: GEAN) hereby publishes the year-end report for the period 1 January - December 31, 2023. The year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:"2023 was a year when we increased our presence in the microbiome testing market and took a leap forward in our commercialization journey. We have further developed and enhanced our GA-map® platform, entered into new distribution agreements, and

Ratos AB – change in number of shares and votes

The fifth opportunity to exercise warrants according to the incentive program for the CEO and other key personnel in Ratos decided on by the 2019 Annual General Meeting was completed in February 2024. Through the exercise of 329,200 warrants, the number of Class B shares increased by 329,200 and the number of votes by 32,920. After the increase, the share capital amounts to SEK 1,029,563,917.20.  Before   After exercise of warrants and conversion, no.exercise ofwarrantsandconversion,no.Class A 84,637,060   Class A shares: 84,637,060

Sanolium contemplates issuance of new senior secured bonds, announces a conditional tender offer for its outstanding 2019/2024 bonds and gives a conditional call notice of early redemption

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW Sanolium AB (publ) (the “Company” or “Sanolium”) has mandated DNB Markets, a part of DNB Bank ASA, Sweden Branch as Global Coordinator and Joint Bookrunner and Carnegie Investment Bank AB (

Flexion releases a trading update and estimates a quarterly revenue record in Q4 2023

LONDON, 29th of February 2024 – Flexion Mobile Plc (Nasdaq: FLEXM), the games marketing company releases a trading update for Q4 2023. During the quarter monthly revenue records were broken several times which resulted in an all-time high for the quarter with an estimated total revenue of GBP 24.3m. The growth was driven both by newly launched titles, existing titles in the top-end of our portfolio as well as Audiencly’s 7vsWild project. This is in line with the revenue guidance of GBP 22-29m for the quarter. Estimated quarter-on-quarter revenue growth for Q4 was 64% and estimated

Foresees a noticeable increase of customers, volume, and sales in 2024

STOCKHOLM - February 29, 2024 - Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, saw important pieces fall into place during the fourth quarter, the foremost being our attainment of accreditation as a medical laboratory. This paved the way for making Inify’s diagnostic service fully available to both private and public healthcare providers, resulting in a sales growth of 176% compared to the third quarter. “I dare to claim that our operations are unique – in Sweden, and internationally. Our ambition is to stay at the forefront in terms of

There are no items matching the current filter
There are no more items matching the current filter
Back to top